Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor

Vaccines: further consolidation through Sanofi cash bid for Acambis

Sanofi Pasteur's offer, valuing Acambis at GBP276m, will give the French pharmaceutical firm extended access to Acambis's large vaccine pipeline, particularly to a universal influenza vaccine candidate and a Clostridium difficile vaccine. The acquisition represents a further important consolidation step in the growing vaccines market, leaving Austria's Intercell as the next big takeover target.

Published By Datamonitor

UCB: Cimzia making good progress

A phase II clinical trial involving Cimzia, UCB and Nektar's anti-TNF alpha antibody, has demonstrated it to be effective and safe in treating psoriasis. However, despite this latest positive news, and Cimzia's advantages over other biologics, the drug candidate's anticipated late entry to the psoriasis drug market will have a negative impact upon its chances of success.

Published By Datamonitor

Targacept: potential shift in research focus for ADHD candidate

Targacept's investigational neuronal nicotinic receptor agonist has failed to meet its primary endpoint in a Phase II trial in adults with attention deficit hyperactivity disorder. Datamonitor expects that future development focus for TC-5619 will shift towards schizophrenia, in view of Phase II data demonstrating efficacy in the treatment of cognitive dysfunction associated with the condition.

Published By Datamonitor

Stroke: UK has lowest usage of CT brain scans

Published By Datamonitor

Significant changes in store for growing HIV market

Worth $8 billion in 2006, the HIV market is expected undergo significant changes as it expands to an estimated $11.5 billion in 2016. Patent expiries on key drugs and product launches in new and existing classes are set to reshape the HIV treatment paradigm. One player set to lose out as its ageing HIV portfolio loses its patent protection is the current market leader, GlaxoSmithKline.

Published By Datamonitor

Shire Pharmaceuticals: transatlantic growth spurt

Published By Datamonitor

Schizophrenia: suffered by 1.3% of world population

Published By Datamonitor

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor